Context. “ Compound 23 ” (Merck) is a selective oral cathepsin K (CatK) inhibitor intended for osteoarthritis. Osteoarthritis affects around 15% of the population, and current treatments offer only symptom relief, highlighting the need for targeted treatments. Prior to the “compound 23”, several CatK inhibitors had reached clinical [...]
3 minute read
Sep. 28, 2022
“Compound 23 ” (Merck) is a Selective Oral Cathepsin K (CatK) Inhibitor
compound 23
oral CAT K inhibitior reduced uCTX-I levels in dog model from opt of a previously disclosed cmpd Bioorg. Med. Chem. Lett. Merck, West Point, PA
Loading...
